F5 and hyperlipoproteinemia: Specifically, “#0” relates to gender and myocardial infarction; “#1” relates to myocardial infarction and acute myocardial infarction; “#2” relates to tissue plasminogen activator and coagulation factor V mutations; “#3” relates to smoking and intensive care units; “#4” relates to hyperlipoproteinemia and ApoE gene polymorphisms; “#5” relates to apolipoprotein B and young patients; “#7” relates to atherosclerosis and risk factors; “#11” relates to coagulation factor VII and genetic polymorphisms; and “#12” relates to female and gender characteristics.